STSA · Satsuma Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| R&D | $44.09M | $37.63M | $36.27M | $4.19M |
| SG&A | $15.13M | $13.53M | $12.06M | $754.0K |
| Total Operating Expenses | $70.95M | $51.17M | $48.33M | $4.95M |
| D&A | $510.0K | $393.0K | $239.0K | $10.0K |
| Operating Income | ($70.95M) | ($51.17M) | ($48.33M) | ($4.95M) |
| Interest Expense | $13.0K | $163.0K | $350.0K | $15.0K |
| Income Tax | $0 | $0 | $1.0K | $1.0K |
| Net Income | ($70.06M) | ($51.17M) | ($47.56M) | ($5.17M) |
| EPS - Basic | ($1.75) | - | - | - |
| EPS - Diluted | ($1.75) | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Cash & Equivalents | $16.43M | $15.84M | $36.33M | $22.75M |
| Accounts Receivable | - | - | - | - |
| Inventory | - | - | - | - |
| Accounts Payable | $1.91M | $1.47M | $3.38M | $4.28M |
| Current Assets | $54.81M | $99.85M | $73.79M | $114.74M |
| Total Assets | $54.94M | $109.83M | $81.03M | $126.28M |
| Current Liabilities | $8.12M | $8.49M | $8.05M | $7.97M |
| Long-term Debt | - | $833.0K | $2.83M | $4.83M |
| Total Liabilities | $8.12M | $8.49M | $9.10M | $10.94M |
| Stockholders' Equity | $46.82M | $101.34M | $71.94M | ($326.0K) |
| Retained Earnings | ($211.79M) | ($141.74M) | ($90.56M) | ($43.00M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Operating Cash Flow | ($51.52M) | ($43.00M) | ($42.33M) | ($4.32M) |
| Investing Cash Flow | $43.37M | ($50.78M) | $58.00M | ($58.0K) |
| Financing Cash Flow | $8.74M | $73.28M | ($2.10M) | $10.93M |
| CapEx | $472.0K | $2.03M | $5.17M | $58.0K |
| Free Cash Flow | ($51.99M) | ($45.03M) | ($47.49M) | ($4.38M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Profitability | ||||
| Gross margin | - | - | - | - |
| Operating margin | - | - | - | - |
| EBITDA margin | - | - | - | - |
| Net margin | - | - | - | - |
| Free cash flow margin | - | - | - | - |
| FCF / Net income | 0.74 | 0.88 | 1.00 | 0.85 |
| R&D / Revenue | - | - | - | - |
| SG&A / Revenue | - | - | - | - |
| Effective tax rate | - | - | - | - |
| Return on assets | -127.5% | -46.6% | -58.7% | -4.1% |
| Return on equity | -149.6% | -50.5% | -66.1% | 1586.5% |
| Return on invested capital | - | -39.6% | -51.1% | -86.7% |
| Liquidity | ||||
| Current ratio | 6.75 | 11.76 | 9.17 | 14.40 |
| Quick ratio | 6.75 | 11.76 | 9.17 | 14.40 |
| Cash ratio | 2.02 | 1.86 | 4.51 | 2.85 |
| Leverage | ||||
| Debt / Equity | - | 0.01 | 0.04 | -14.83 |
| Debt / Assets | - | 0.01 | 0.03 | 0.04 |
| Debt / EBITDA | - | - | - | - |
| Interest coverage | -5457.5x | -313.9x | -138.1x | -329.8x |
| Equity multiplier | 1.17 | 1.08 | 1.13 | -387.35 |
| Liabilities / Assets | 0.15 | 0.08 | 0.11 | 0.09 |
| Efficiency | ||||
| Asset turnover | - | - | - | - |
| Inventory turnover | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days inventory outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Cash conversion cycle | - | - | - | - |
| Valuation | ||||
| P / E | - | - | - | - |
| P / B | - | - | - | - |
| P / S | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| Growth | ||||
| Revenue growth (YoY) | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - |
| Operating income growth (YoY) | -38.7% | -5.9% | -876.9% | - |
| Net income growth (YoY) | -36.9% | -7.6% | -819.6% | - |
| EPS growth (YoY) | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - |
| FCF growth (YoY) | -15.5% | 5.2% | -984.5% | - |
| FCF CAGR (5y) | - | - | - | - |
| Book value growth (YoY) | -53.8% | 40.9% | - | - |
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Satsuma Pharmaceuticals against the 5 most active filers in the same SIC group.